August 10, 2011 (Durham, North Carolina) — A major clinical trial showing that rivaroxaban (Xarelto, Bayer/Johnson & Johnson) is noninferior to dose-adjusted warfarin for the prevention of stroke or ...

The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday. Rivaroxaban 2.5 mg tablets from Lupin and Taro are now considered therapeutic ...

The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the ...

At both 6 months and 12 months follow-up, the rivaroxaban group was found to have more of these events than the apixaban group. Credit: Getty Images. In patients with atrial fibrillation and valvular ...

Heart failure is associated with activation of thrombin-related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin ...

The oral anticoagulant rivaroxaban is a safe and effective alternative to vitamin K antagonists for patients with atrial fibrillation (AF) undergoing cardioversion. This finding from the X-VeRT trial ...

A new randomized trial lays the groundwork for the direct oral anticoagulant rivaroxaban (Xarelto; Janssen/Bayer) as a potential treatment option for children with venous thromboembolism (VTE). Its ...

CHICAGO, IL—Low-dose rivaroxaban reduces thromboembolic events in patients with worsening heart failure, reduced ejection fraction, CAD, and normal sinus rhythm, a post hoc analysis of the COMMANDER ...

Please provide your email address to receive an email when new articles are posted on . The BRAIN-AF trial enrolled adults younger than 65 years who had atrial fibrillation but no other risk factors ...

Please provide your email address to receive an email when new articles are posted on . Acute left ventricular thrombus occurs in about 3% of all patients with STEMI. Rivaroxaban demonstrated similar ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of rivaroxaban, having considered evidence on the nature of venous thromboembolism and the value placed on ...

The RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm. Researchers ...